{"groups":[{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 15 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 20 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG000","title":"Phase I: Dose Level -1"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG001","title":"Phase I: Dose Level 0"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG002","title":"Phase I: Dose Level 1"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 45 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG003","title":"Phase I: Dose Level 2"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG004","title":"Phase II: Dose Level 0"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"FG005","title":"Phase II: Dose Level 1"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"22"},{"groupId":"FG005","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"22"},{"groupId":"FG005","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}